Gastric cancer indocyanine green lymph node navigation surgery: systematic review

Beatrice Molteni,1 Paola Porsio,1 Sarah Molfino,1 Marie Sophie Alfano,1 Sara Benedicenti,1 Fausto Catena,2 Luca Ansaloni,3 Nazario Portolani,1 Gianluca Baiocchi1

1Department of Surgery, ASST Spedali Civili Brescia, Brescia; 2Department of Emergency Surgery, Maggiore Hospital, Parma; 3Department of General Surgery, Cesena Hospital, Cesena, Italy

Abstract

Sentinel lymph node (LN) biopsy is a common practice to determine if a lymphadenectomy is needed in various malignancies. Recent studies have investigated the possibilities to extend sentinel LN biopsy in gastric cancer. Indocyanine green (ICG) is a diagnostic reagent recently introduce in sentinel LN biopsy field. This review aims to determinate the feasibility to used ICG to detect sentinel LN in gastric cancer.

Introduction

Indocyanine green (ICG) is a diagnostic reagent used since long time for assessment of hepatic function and cardiac output. It is also used as a dye tracer for gastric cancer as the blue dye. Unfortunately ICG was not well observed by naked eyes, than devices to better detect ICG were developed. ICG absorbs light in the near infrared range between 600 to 900 nm and emits fluorescence between 750 to 950 nm. Near infrared fluorescence imaging system developed are the following: Photodynamic Eye (PDE, Hamamatsu Photonics, Hamamatsu, Japan) imaging camera system,1 SPY system (Novadaq Technologies, Concord, ON, Canada) and the Fluobeam (Fluoptics, Grenoble, France). Several others imaging systems have been used in clinical studies but are not available in the market as: HyperEye (HEMS)2 (Kochi Medical School, Kochi, Japan), the FLARE and Mini-FLARE3 (Beth Israel Deaconess Hospital, Boston, MA, USA), the FDPM imager4 (Texas Medical Center, Houston, TX, USA), and a prototype camera system from Munich5 (Technical University Munich, Munich, Germany and SurgOptix Inc., Redwood Shores, CA, USA).

Sentinel LN is defined as a node that directly receives lymphatic drainage from a primary tumor.6 Sentinel LN biopsy is a common practice to determine if a lymphadenectomy is needed in various malignancies, for example breast and skin cancer. Recently gastric cancer sentinel node biopsy was investigated. Prospective studies have successfully demonstrated the feasibility of sentinel LN biopsy in gastric cancer.7-10 Except for JCOG0302 trial that shown high false negatives, that was probably because just one plan for intraoperative histological examination was not an appropriate method.11 Various methods are described to map sentinel LN as: isosulfan blue and ICG were used as dye tracer. Successively radioactive tracer with Tecnezium-99 colloid was introduced, alone or associate with dye tracer. Dual tracer method for sentinel LN mapping is confirmed to be safe and effective.12 Recently ICG fluorescence method was introduced, using near infrared light to detect sentinel LN.

Our goal is to determinate the feasibility of single tracer ICG sentinel LN mapping in gastric cancer patients.

Methods of research

Literature search strategy

We carried out electronic research during July 2017. PubMed, EMBASE and Cochrane Library database were examined. Key words for the research were gastric or stomach cancer, indocyanine green, and lymph node. Only English language articles were included. References from included studies were screened to search for additional potentially relevant articles.

Inclusion and exclusion criteria

We consider as inclusions criteria the following: original articles concerning LN navigation surgery in gastric cancer using ICG with near infrared light. Exclusion criteria are as follow: reviews, case reports, meta-analyses, abstract, posters or letters; animal experimental trial; dye

Correspondence: Beatrice Molteni, Department of Surgery, ASST Spedali Civili Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
E-mail: beatrice.molteni@hotmail.com

Key words: Gastric cancer; indocyanine green; sentinel lymph node.

Contributions: MB and PP, study and manuscript conception, online search and article selection; BG, re-checking and solve doubt; MS, AMS, BS, CF, AL, PN, revising and contribute to final version.

Conflict of interest: the authors declare no potential conflict of interest.

Received for publication: 26 February 2018.
Revision received: 25 March 2018.
Accepted for publication: 19 April 2018.

©Copyright B. Molteni et al., 2018
Licensee PAGEPress, Italy
Journal of Peritoneum (and other serosal surfaces) 2018; 3:97
doi:10.4081/joper.2018.97

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
ICG tracer detected by naked eye; studies that include dual tracer; studies without sufficient data.

Online search and article selection were performed by two investigators independently (M.B. and P.P.) a third investigator rechecked original articles and discuss any doubt (B.G.).

Data extraction and quality assessment

Data were extracted by two authors (M.B. and P.P.) and excel table were filled including author and publication time, number of patients, clinical T stage, surgical method (laparoscopic or open), injection method, time of injection, dose of ICG injected, type of camera used and test results (identification rate, false negative and number of LN included into basin). Identification rate was defined as the number of patients who underwent a successful sentinel LN biopsy by the number of patients in whom a sentinel LN biopsy was attempted. False negative was defined as a negative sentinel LN with positive LN non-sentinel. False negative rate was the number of false negative by the number of LN metastases (Figure 1).

Results

A total of 390 records were identified: 132 PubMed, 238 EMBASE, 18 Cochrane and 2 from others sources. After duplicate removal a total of 266 records were screened and we found that of them 184 were irrelevant; the main part regard sentinel LN in gastric cancer without ICG usage, or ICG involved in others surgical techniques. Finally 82 articles remained for potentially inclusion, and full text was read. 64 full texts were excluded in the final screening. The main reasons for excluding studies were: non original articles (such as review), animal experiment, in vitro experiment, the use of dual tracer and the use the dye tracer with naked eye.

18 studies were included in the review. Publication time was from 2004 to 2017. The sample size varied from 3 to 212 patients. Clinical T stage varied from T1 to T4, with a higher prevalence of T1 and T2, all N0 and M0. Both laparoscopic and open surgery technique were included.
No adverse event associated with sentinel LN biopsy or ICG injection was described. ICG was injected from 3 days before surgery to intraoperatively, injection way was submucosal or subserosal. Camera system used to detect sentinel LN were PDE, infrared ray electronic endoscopy (IREE), miniFLARE, Infrared ray laparoscopic system (IRLS), PINPOINT, HEMS. Amount of ICG varied from 0.2 mL to 1 mL x 4 point of injection, dilution 33 μg/mL to 1.25 mg/0.5 mL. Identification rate range was between 90.90% and 100% average of sentinel LN detected was 2.9-10.5. False negative rate varied from 0% to 60%.

**Discussion**

**False negative**

Higher false negative rate was found from Kusano *et al.* (60%) he showed that increasing pathological T stage from T1 to T3 a higher false negative rate was found (T1 33.3%, T2 66.7%, T3 75%) (Table 1). Also Ishikawa *et al.* found a high percentage of false negatives (50%). They found 2 metastatic LN, and 1 false negative in an obese patient, the LN was located in sentinel LN basin, it was not bright at laparoscopic founding, but a positive staining was observed postoperatively. The same appended to Kinami, 1 patient had LN micrometastases diagnosed in a LN non-bright intraoperatively, but postoperative was found to be staining. Other bright LN in the same basin was found to be metastatic cutting other slices of the paraffin blocks. Although high false negative rate was found by some author, the false negative LN was located in the same LN basin. The mislead false negative can be overcome examining all LN founded in LN basin.

Tajima *et al.* had 35% false negative rate. The pT1 of cT1 percentage was 81%, and pT2 and pT3 was respectively 16.2% and 2.7%. For cT2 and cT3 the percentage of pT1 was 5.3%, and for pT2 and pT3 was respectively 52.6% and 42.1%. False negative rate for cT1 was 14.3, and for cT2 and cT3 50%.16

Tajima *et al.* had a false negative rate lower in laparoscopic sentinel LN navigation surgery (24%). False negative rate was found to be higher in T2 group vs T1 (28.6% vs 20%). It was shown that the risk of metastasis in LN outside lymphatic basin in patients without metastases in sentinel LN was 0%, and was 23% in patients with sentinel LN metastases (12.5% in T1 and 40% in T2).17 The concept of sentinel LN as lymphatic basin dissection can probably predict the absence of metastases outside of lymphatic basin. A selective lymphadenectomy can be performed avoiding the extended lymphadenectomy.

Tummers *et al.* analyzed cTx patients, their false negative rate was 24%. Accuracy rates decrease with the T state, for pT1, pT2, pT3 and pT4 were 100%, 100%, 100%, 90% and 0%. False negative were found in T3 and T4 tumours, with a large tumor diameter. In 8/22 patients sentinel LN were detected outside of standard resection plan. In this study 1 of the false negative LN was found in the same basin of one sentinel LN. The experience of Tummers,16,17 Kusano,13 showed as increasing T stage increase the risk of false negative. Probably this technique should be applied only in T1 stage. Unfortunately western experience is poor of early stage gastric cancer. Tummers18 report the mayor western experience in sentinel LN navigation surgery, and demonstrated that in T2, T3 and T4 stage a standard lymphadenectomy should probably be the best choice. Asian experience is more positive regarding this new technique. The mayor part of gastric cancer is an early stage that lead to promote this technique to avoid unnecessary lymphadenectomy and probably less invasive resection.

**ICG injection**

In a prospective multicenter trial Takahashi demonstrate the superiority of infrared light observation instead of naked eye observation concerning identification rate (100% vs 80%).19,20 confirmed

| Table 1. False negative. |
|--------------------------|
| Author           | Year | cT-stage | pT-stage | N° patients | N° metastatic sentinel LN | False negative | False negative rate (%) |
| Takahashi N       | 2017 | T1       |          | 44          | 7                          | 0              | 0                        |
| Kinami S          | 2016 | T1       | T1a 29/T1b 31/T2 10/T3 2 | 72          | 11                          | 1              | 9                        |
| Takahashi N       | 2016 | T1/T2    |          | 36          | 5                          | 0              | 0                        |
| Tummers Q         | 2016 | Tx       | Tx2/T1 5/T2 4/T3 1          | 22          | 8                          | 2              | 25                       |
| Yano K            | 2011 | T1/T2    |          | 130         | 31                         | 0              | 0                        |
| Miyashiro I       | 2011 | T1       | 4 T1a/5 T1b/1 T2            | 10          | 3                          | 1              | 33                       |
| Nimura H          | 2004 | T1/T2    |          | 84          | 11                         | 0              | 0                        |
| Ishikawa K        | 2007 | T1       | pT1 (14)/pT2 (2)           | 16          | 2                          | 1              | 50                       |
| Yoshida M         | 2012 | T1/T2    |          | 13          | 1                          | 0              | 0                        |
| Kelder W          | 2010 | T1       | 183 T1/25 T2/4 T3           | 212         | 34                         | 1              | 3                        |
| Kusano M          | 2008 | Tx       | T1/T2/T3                    | 22          | 10                         | 6              | 60                       |
| Tajima Y          | 2010 | T1 T2    | S2T1/21T2/4T3               | 77          | 17                         | 4              | 24                       |
| Ohdaira H         | 2007 | Tx       | T1                  | 52          | 2                          | 0              | 0                        |
| Miyashiro I       | 2008 | T1       |          | 3           | 0                          | 0              | 0                        |
| Ohdaira H         | 2009 | T1 T2    | 23T1/7 T2                  | 30          | 4                          | 0              | 0                        |
| Ohdaira H         | 2009 | T1 T2    |          | 14          | 3                          | 0              | 0                        |
| Ohdaira H         | 2017 | T1/T2    |          | 6           | 1                          | 0              | 0                        |
| Tajima Y          | 2009 | 37 T1/19 T2 T3 | 23 T1/16 T2/8 T3 | 56          | 17                         | 6              | 35                       |
by other study in which identification rate was similar (100% vs 78%)\textsuperscript{13} (Table 2). Identification rate was 98.8% in Nimura et al. study. In one patient, it was not possible to identify sentinel LN probably because the patient was extremely obese. ICG alone was able to detect sentinel LN that includes metastasis in 7 patients instead of 11 LN identified with IREE.\textsuperscript{22} Kelder as well has one obese patient in which was not possible detect sentinel LN with IREE. The identification rate was much superior with IREE than naked eye.\textsuperscript{19} ICG originally was used as a dye tracer ad methylene blue. Since near infrared light was introduced in the clinical practice, identification rate of sentinel LN is increased. This new technique seems to be safe and effective in sentinel LN navigation surgery.

Kimani et al proposed as optimal tracer setting to use with the PDE an endoscopic submucosal injection of 0.5 ml of 50 µg/mL ICG at four points surrounding the tumor the day prior to surgery. Some preliminary cases were examined with an ICG concentration of 2.5 mg/mL, 125 µg/mL, 125 µg/mL, 50 µg/mL, and 5 µg/mL for 0.5 mL x 4 injection point. They decide to evaluate 0.2 mL x 4 and 0.5 mL x 4 points, the median number of bright LN was not significantly different between two groups: 6 (range 3-11) for 0.5 mL and 6 (2-7) for 0.2.\textsuperscript{15}

Yoshida et al. have developed a new device for near infrared light, it can be used under room light. He tried the first 2 preliminary cases one with 100 µg/mL ICG 1 day before surgery, and the second one 25 µg/mL the day before too. The first case was too intense and too many fluorescence-positive LN were detected. In the second patient the fluorescence was too faint. Than 50 µg/mL ICG injection was used as a dye tracer ad methylene blue. Since near infrared light was introduced in the clinical practice, identification rate of sentinel LN is increased. This new technique seems to be safe and effective in sentinel LN navigation surgery.

Takahashi et al. attempted to quantitatively assess the visual evaluation of ICG image. They grouped on a black table LN dissected in ICG positive lymphatic basin into two group: ICG positive and ICG negative. Then LN were photographed under infrared light observation in a black box and software analyzed the intensities. They demonstrated the intensity was significantly different between ICG-positive and ICG negative LN (0.323±1.56 vs 0.639±1.93).\textsuperscript{21}

ICG injection timing is debated. Intraoperative injection is less invasive for patients instead an endoscopy performed the day prior to surgery. Tajima et al. in their study resulted that the mean number of SNs was significantly higher in the preoperative ICG injection group than in the intraoperative ICG injection group (9.9±7.5 vs 4.1±5.0, P<0.0003). Preoperative ICG injection was superior in terms of the accuracy and false negative rates (100% vs 73.9%, P=0.0039 and 0% vs 60.0%, P=0.0345). Even is more invasive, preoperative ICG injection seems to be superior than intraoperative.\textsuperscript{16}

ICG lymphography might could helps in identify potentially pathological LN outside of standard resection plan, and could guide extended lymphadenectomy even in patients pretreated with chemotherapy.\textsuperscript{15} Unfortunately the literature is poor of articles that include advanced gastric cancer LN navigation surgery. More studies are needed to prove the effectiveness of ICG in advanced gastric cancer. Some authors demonstrate that increasing T stage, false negative rate is higher.\textsuperscript{15} Probably pathological LN lose their function, the in and the outflow, and that make impossible to inflow ICG.\textsuperscript{18}

Sentinel LN basin is a lymphatic area including SLNs and downstream lymphatic flow. Tummers confirms that sentinel LN basin dissection is better than LN picking method.\textsuperscript{18} Kelder confirm the higher intraoperative detection rate with frozen section of LN metastases: 92.3% for basin dissection vs 50% for the picking method.\textsuperscript{19}

Ohdaira H support the LN basin dissection, additional dissection

### Table 2. ICG Injection.

| Author       | Year | ICG injection | Amount of ICG | Submucosal/subserosal | Time from injection to biopsy | Average of LN per patient | SLN identification rate (%) |
|--------------|------|---------------|---------------|-----------------------|-----------------------------|--------------------------|-----------------------------|
| Takahashi N  | 2017 | I             | 0.5 mL        | SM                    | 20 min                      | 7.9±5.6                  | 100                         |
| Kinami S     | 2016 | D             | 0.5 mL x 4: 0.2x4 | SM                    | 24 h                         | 6                         |                             |
| Takahashi N  | 2016 | I             | 0.5 mL x 4 (5 mg/mL) | SM                    | 20 min                      | 9.2±5.9                  | 100                         |
| Tummers Q    | 2016 | I             | 0.4 mL x 4 ICG and Nanocolloid (1.6 mL ICG solution=0.05 mg ICG + 0.1 mg nanocolloid) | SM/SS               | 0 min                        | 3.1                       | 95.45                       |
| Yano K       | 2011 | I             | 0.5 mL x 4 (0.5 mg/mL) | SM                    | 20 min                      | 100                       |                             |
| Miyashiro I  | 2011 | I             | 2-4 mL (0.25-1.25 mg/0.5 mL) | SM                    | 5 min                        | 3.1±1.5                  | 100                         |
| Nimura H     | 2004 | I             | 0.5 mL x 4 (5 mg/mL) | SM                    | 20 min                      | 10.5±6.6                 | 98.80                       |
| Ishikawa K   | 2007 | I             | 0.5 mL x 4 (5 mg/mL) | SM                    | 20 min                      | 2.9                       | 100                         |
| Yoshida M    | 2012 | D             |               | SM                    | 24 h                         | 3.6±2.1                  | 100                         |
| Kelder W     | 2010 | I             | 0.5 mL (5 mg/mL) | SM                    | 20 min                      | 6                        | 99.52                       |
| Kusano M     | 2008 | I             | 0.5 mL x 4 (0.5%) | SS                    | 20 min                      | 3.6±4.5                  | 90.90                       |
| Tajima Y     | 2010 | I, 3D         | 0.5 mL x 4 (0.5%) | SM/SS               | 1-3 day/Intraop             | 7.5                       | 94.80                       |
| Ohdaira H    | 2007 | I             | 0.5 mL x 4 (5 mg/mL) | SM                    | 20 min                      | 100                       |                             |
| Miyashiro I  | 2008 | I, D          | 2-4 mL        | SM                    | Immediately/24 h             | 3                        | 100                         |
| Ohdaira H    | 2009 | I             | 0.5 mL x 4 (5 mg/mL) | SM                    | 20 min                      | 4.8                       | 100                         |
| Ohdaira H    | 2009 | I             | 0.5 mL x 4 (5 mg/mL) | SM                    | 20 min                      | 100                       |                             |
| Ohdaira H    | 2017 | D             | 50 g/mL for 5 case; 33 g/mL for 1 case | SM | 7±4.7                  | 100                       |
| Tajima Y     | 2009 | I, 3D         | 0.5 mL x 4 (0.5%) | SM/SS               | 24 h                        | 7.2±7                     | 94.40                       |
of ICG - positive lymphatic basin detected by LN navigation surgery should be performed to confirm the absence of LN metastases.²⁴

Concerning the pathological examination, the use of immunohistochemistry with anti-cytokeratin antibody is demonstrated to be superior to hematoxylin and eosine (H&E) in diagnosing of LN metastasis. 13% of patients diagnosed with no metastasis by H&E staining were judged LN positive by IHC staining.²⁵ Detection of micrometastases is an important factor to follow up because of the increased risk of recurrence.²⁶ Anyway all LN with micrometastases was ICG positive, and included in SN basin dissection.²⁵ One sentinel LN with micro metastases was missed at intraoperative evaluation, but detected with IHC.²⁷

**Camera system**

Nimura et al. started the evaluation of sentinel LN using ICG fluorescence-guided method with IREE.²⁷ Kinami et al. started to use PDE for ICG fluorescence detection (Table 3). IREE was used in 8 studies and 6/8 studies had 100% detection rate, and the lowest rate was 98.8%. PDE was used in 6 studies, and had a range of identification rate from 90.9% to 94.8% using PDE alone, but associated with colour or IREE raised 100%. IRLS was firstly described from Takahashi et al. for laparoscopic detection of sentinel LN, the identification rate with this device was 100%. New cameras were described from others author, Mini Flare with identification rate 95.45%, HEMS and PINPOINT identification rate were 100% both. False negative rate range for PDE was from 9% to 60%, except for Miyashiro that did not found any metastatic LN. The range for IREE was from 0% to 50%, in 6/8 studies the percentage was 0%. Different types of camera were used in different studies. More studies are needed to compare the camera type.

Detection rate and the mean number of sentinel LN were similar for laparoscopic and open surgery (94.7% vs 94.9%, 7.9 vs 7.2). False negative rate was 25% for laparoscopic surgery and 23.1% for open surgery. Ohdaira et al. support the use of ICG for sentinel LN detection even in patients who had received previously an endoscopic resection.²⁷-²⁹ There is no difference in laparoscopic and open surgery.

**Conclusions**

ICG fluorescence navigation surgery seems to be safe in detection of sentinel LN in gastric cancer. High false negative rate was found in some studies, probably because the small number of the sample and in some cases in obese patients. Increasing T stage increase the risk of false negative. May IHC can helps to better detect micrometastases and to reduce false negative. More studies are needed to overcome this problem. New cameras may can help to better detect sentinel LN. ICG navigation surgery seems to be safe in both, open and laparoscopic approaches. More studies are needed to better understand the role of ICG in gastric cancer navigation surgery.

**References**

1. Tagaya N. Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer. Am J Surg 2008;195:850-3.
2. Handa T. New device for intraoperative graft assessment: HyperEye charge-coupled device camera system. Gen Thorac Cardiovasc Surg 2010;58:68-77.
3. Troyan S. The FLARE intraoperative near-infrared fluores-

**Table 3. Camera System.**

| Author       | Year | Camera                                      | Surgery               | Sentine LN identification rate (%) | False negative rate (%) |
|--------------|------|---------------------------------------------|-----------------------|------------------------------------|-------------------------|
| Takahashi N  | 2017 | IRLS (infrared ray laparoscopic system)     | Laparoscopy           | 100                                | 0                       |
| Kinami S     | 2016 | PDE                                         | 32 open/40 laparoscopy| 9                                  |
| Kusano M     | 2008 | PDE                                         | 18 open/4 laparoscopy | 90.90                              |
| Tajima Y     | 2010 | PDE                                         | 17 open/19 laparoscopy| 100                                | 0                       |
| Yano K       | 2011 | IREE                                        | 65 open/19 laparoscopy| 96.80                              |
| Miyashiro I  | 2011 | PDE + color                                 | 65 open/19 laparoscopy| 96.80                              |
| Ohdaira H    | 2007 | IREE                                        | 65 open/19 laparoscopy| 96.80                              |
| Ohdaira H    | 2008 | PDE + IREE                                  | 65 open/19 laparoscopy| 96.80                              |
| Ohdaira H    | 2009 | IREE                                        | 65 open/19 laparoscopy| 96.80                              |
| Ohdaira H    | 2017 | PINPOINT                                    | 65 open/19 laparoscopy| 96.80                              |
| Tajima Y     | 2009 | PDE                                         | Open/19 laparoscopy   | 96.80                              |
cence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 2009;16:2943-52.

4. Marshall M. Near-infrared fluorescence imaging in humans with indocyanine green: a review and update. Open Surg Oncol J 2010;2:12-25.

5. Crane L. Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept. Mol Imaging Biol 2010.

6. Morton D. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:329-99.

7. Hirasutsuka M. Application of sentinel node biopsy to gastric cancer surgery. Surgery 2001;129:335-40.

8. Carlini M. Sentinel node in gastric cancer surgery. J Exp Clin Cancer Res 2002;21:469-73.

9. Ichikura T. Sentinel node concept in gastric carcinoma. World J Surg 2002;26:318-22.

10. Kitagawa Y. Radio-guided sentinel node detection for gastric cancer. Br J Surg 2002;89:604-8.

11. Miyashiro I. High false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302. Gastric Cancer 2014;17:316-23.

12. Kitagawa Y. Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. J Clin Oncol 2013;31:3704-10.

13. Kusano M. Sentinel node mapping guided by indocyanine green fluorescence imaging: a new method for sentinel node navigation surgery in gastrointestinal cancer. Dig Surg 2008;25:103-8.

14. Ishikawa K. Laparoscopic sentinel node navigation achieved by infrared ray electronic endoscopy system in patients with gastric cancer. Surg Endosc 2007;21:1131-4.

15. Kinami S. Optimal settings and accuracy of indocyanine green fluorescence imaging for sentinel node biopsy in early gastric cancer. Oncol Lett 2016;11:4055-62.

16. Tajima Y. Sentinel node mapping guided by indocyanine green fluorescence imaging in gastric cancer. Ann Surg 2009;249:58-62.

17. Tajima Y. Sentinel node mapping guided by indocyanine green fluorescence imaging during laparoscopic surgery in gastric cancer. Ann Surg Oncol 2010;17:1787-93.

18. Tummers Q. Near-infrared fluorescence sentinel lymph node detection in gastric cancer: A pilot study. W J Gastroenterol 2016;22:3644-51.

19. Kelder W. Sentinel node mapping with indocyanine green (ICG) and infrared ray detection in early gastric cancer: an accurate method that enables a limited lymphadenectomy. J Cancer Surg 2010;36:552-8.

20. Takahashi N. Laparoscopic sentinel node navigation surgery for early gastric cancer: a prospective multicenter trial. Langenbecks Arch Surg 2017;404:27-32.

21. Takahashi N. Quantitative assessment of visual estimation of the infrared indocyanine green imaging of lymph nodes retrieved at sentinel node navigation surgery for gastric cancer. BMC Surg 2016 [Epub ahead of print].

22. Nimura H. Infrared ray electronic endoscopy combined with indocyanine green injection for detection of sentinel nodes of patients with gastric cancer. Br J Surg 2004;91:575-9.

23. Yoshida M. Indocyanine green injection for detecting sentinel nodes using color fluorescence camera in the laparoscopy-assisted gastrectomy. J Gastroenterol Hepatol 2012;12:29-33.

24. Ohdaira H. Validity of modified gastrectomy combined with sentinel node navigation surgery for early gastric cancer. Gastric Cancer 2007;10:117-22.

25. Yano K. The efficiency of micrometastasis by sentinel node navigation surgery using indocyanine green and infrared ray laparoscopy system for gastric cancer. Gastric Cancer 2012;15:287-91.

26. Saito H. Recurrence in early gastric cancer: presence of micrometastasis in lymph node of node negative early gastric cancer patients with recurrence. Hepatogastroenterol 2007;54:620-4.

27. Ohdaira H. Tailoring treatment for early gastric cancer after endoscopic resection using sentinel node navigation with infrared ray electronic endoscopy combined with indocyanine green injection. Digest Surg 2009;26:276-81.

28. Miyashiro I. Detection of sentinel node in gastric cancer surgery by indocyanine green fluorescence imaging: comparison with infrared imaging. Ann Surg Oncol 2008;15:1640-3.

29. Ohdaira H. The possibility of performing a limited resection and lymphadenectomy for proximal gastric carcinoma based on sentinel lymph node navigation. Surg Today 2009;39:1026-31.